Elizabeth M. Jaffee, MD, FAACR
Deputy Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Robert H. Vonderheide, MD, DPhil
Director, Abramson Cancer Center of the University of Pennsylvania; Hanna Wise Professor in Cancer Research, University of Pennsylvania Perelman School of Medicine
Pancreatic ductal adenocarcinoma (PDA) is resistant to most forms of therapy and is one of the most deadly types of cancer. The environment that surrounds cancer cells is referred to as the tumor microenvironment. Studies in mice and humans have shown that the PDA tumor microenvironment has unique characteristics that are thought to limit the efficacy of treatment.
The Dream Team uses a "convergence" approach where leading individuals in different scientific fields work together toward understanding and treating PDA.
The Dream Team has been conducting numerous clinical trials using a combination of drugs and is establishing what molecules, or biomarkers, can be measured as a read-out of tumor microenvironment reprogramming. The Team's trials are focusing on new ways to reverse immune suppression in the tumor, either in combination with a vaccine that activates anti-cancer T cells or with chemotherapy. These trials will also contribute to the establishment of a national PDA biobank for identification of immune biomarkers.
Progress to Date
The Team's trials are focusing on new ways to reverse immune suppression in the tumor, either in combination with a vaccine that activates anti-cancer T cells or with chemotherapy. These trials will also establish a national PDA biobank for identification of immune biomarkers. Laboratory studies in mice are being conducted to establish novel multi-agent approaches and to develop biomarkers that will drive the next generation of clinical trials.
Margaret A. Tempero, MD, University of California, San FranciscoLisa M. Coussens, PhD, Oregon Health & Science UniversityDavid C. Linehan, MD, Washington University in St. LouisDafna Bar-Sagi, PhD, NYU Langone Medical CenterIrving L. Weissman, MD, Stanford UniversityDouglas T. Fearon, MD, University of Cambridge, United KingdomSteven D. Leach, MD, Memorial Sloan Kettering Cancer Center
Betty BooherStuart RickersonRichard Vague